Get started
Author

Endip Dhesi

Observed names: Dhesi E, E Dhesi
ORCID: 0009-0009-8175-1175
Observed ORCID: 0009-0009-8175-1175
OpenAlex ID: A5035947119
OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis
2024 · A Hart, M D Martín-Arranz, et al. · Journal of Crohn s and Colitis · 5
PDF
P303 Bowel urgency communication gap between health care professionals and patients with ulcerative colitis in the US and Europe: CONFIDE survey
2023 · Simon Travis, Alison Potts Bleakman, et al. · Poster presentations · 2
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis
2026 · Ailsa Hart, Seyedehsan Navabi, et al. · United European Gastroenterology Journal · 1
Dose Escalation Patterns and Associated Costs of Advanced Therapies for Ulcerative Colitis in France and the United Kingdom: A Retrospective Database Analysis
2025 · Tamás Treuer, Melissa Richards, et al. · ClinicoEconomics and Outcomes Research · 1
P0752 Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
2025 · A Hart, I Blumenstein, et al. · Journal of Crohn s and Colitis · 1
P64 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
2024 · Geert D’Haens, Peter Higgins, et al. · Poster presentations · 1
P73 Effect of mirikizumab on bowel urgency clinically meaningful improvement and remission: phase 3 LUCENT induction and maintenance study results
2023 · Simon Travis, Toshifumi Hibi, et al. · Poster presentations · 1
P72 Efficacy and safety of mirikizumab as maintenance therapy in patients with moderate-severe active ulcerative colitis: phase 3 LUCENT-2 study results
2023 · Marla C Dubinsky, Peter M Irving, et al. · Poster presentations · 1
Tu1063 Colonoscopy for Abdominal Pain: Is It Worth Performing?
2016 · Endip Dhesi, Kalpesh Besherdas · Gastrointestinal Endoscopy · 1
PTU-044 Is there any value in performing a clo test at endoscopy in patients previously having a stool antigen test?
2015 · E Dhesi, B White, et al. · Gut · 1
P169 Efficacy and safety of mirikizumab in week 52 endoscopic responders with crohn’s disease: 3-year vivid-2 open-label extension interim results
2026 · David Laharie, David Clemow, et al. · E-Posters
PDF
CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
2025 · Tariq Ahmad, Peter Irving, et al. · Value in Health
P12 Early symptomatic improvement with mirikizumab induction therapy in patients with moderately-to-severely active crohn’s disease: phase 3 vivid-1 study results
2025 · Bruce E Sands, Min-Hu Chen, et al.
P11 Association of faecal calprotectin with symptomatic, endoscopic, and clinical remission in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab
2025 · Severine Vermeire, Millie Long, et al.
P36 The hidden burden of fatigue in moderate-to-severe crohn’s disease and ulcerative colitis: results from the confide survey
2025 · Stefan Schreiber, Alison Potts Bleakman, et al.
P41 Efficacy and safety of long-term mirikizumab treatment in patients with moderate-to-severe Crohn’s disease
2025 · Bruce Sands, Geert D’Haens, et al.
P25 Efficacy of mirikizumab by baseline disease location in moderately-to-severely active crohn’s disease: results of the phase 3 VIVID-1 study
2025 · Edward Barnes, Peter Bossuyt, et al.
P37 Impact of mirikizumab induction, maintenance, and long-term treatment on disease clearance in ulcerative colitis: post HOC analysis of LUCENT trials
2025 · Jean-Frederic Colombel, Taku Kobayashi, et al.
P40 Disease characteristics associated with bowel urgency in Crohn’s disease: results from the phase 3 VIVID-1 trial
2025 · Geert D’Haens, Bruce E Sands, et al.
P38 Long-term endoscopic and histological outcomes of mirikizumab in moderately-to-severely active ulcerative colitis with up to 3 years of treatment
2025 · Bruce Sands, Taku Kobayashi, et al.
P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants
2025 · Vipul Jairath, Fernando Magro, et al.
P265 Efficacy and safety of the mirikizumab extended induction cohort moderately-to-severely active ulcerative colitis: LUCENT-3 open-label extension study results
2025 · Ailsa Hart, Irina Blumenstein, et al.
Tu1835: EFFICACY AND SAFETY OF THE MIRIKIZUMAB EXTENDED INDUCTION COHORT AT 152 WEEKS OF CONTINUOUS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
2025 · Ailsa Hart, Irina Blumenstein, et al. · Gastroenterology
P66 Corticosteroid-sparing effect in patients with moderately to severely active ulcerative colitis treated with mirikizumab maintenance therapy
2024 · David Laharie, Corey Siegel, et al. · Poster presentations
P93 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately-to-severely active ulcerative colitis
2024 · Ailsa Hart, María Dolores Martín-Arranz, et al. · Poster presentations
Works count: 41
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type